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Introduction
Attention deficit hyperactivity disorder (ADHD) is a
highly disabling neurodevelopmental disorder affect-
ing between 2 and 5% of the school aged population
[5, 15]. Associated with a number of negative out-
comes including poor academic performance as well
as impaired peer and family relationships, [3] ADHD
is one of the most common reasons for referral to
specialist Child Mental Health Services [23]. Most
studies show some symptom decline over time, al-
though the clinical diagnosis of ADHD is recognized
to persist from childhood into adolescence and even
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j Abstract Objective The devel-
opmental trajectory of attention-
deficit hyperactivity disorder
(ADHD) is variable. Utilizing a
longitudinally assessed sample, we
investigated the contribution of
susceptibility gene variants, pre-
viously implicated through pooled
or meta-analyses, to the develop-
mental course of Attention-Deficit
Hyperactivity Disorder over time.
Methods 151 children (aged 6–12)
who met diagnostic criteria for
ADHD were assessed using re-
search diagnostic interviews dur-
ing childhood and 5 years later in
adolescence. Severity was defined
as total number of ADHD symp-
toms at baseline and reassessment.
Association with variants at DRD4,
DRD5, and the dopamine trans-
porter gene, DAT was analyzed
using linear regression. Results
As expected, affected individuals
showed a decline in ADHD sever-
ity over time. The DRD4 48 bp
VNTR 7-repeat and DRD5 CA(n)
microsatellite marker 148 bp risk
alleles were associated with per-
sistent ADHD. Those possessing
the DRD4 7 repeat risk allele
showed less of a decline in severity
at reassessment than those with-
out the risk allele. Conclusions
Those carrying the DRD4 7 risk
allele showed greater symptom
severity at follow-up and less
ADHD reduction over time. These
findings support the hypothesis
that some susceptibility genes for
ADHD also influence its develop-
mental course.
j Key words ADHD – longitudi-
nal – DRD4 – DRD5 –
DAT1
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adulthood in some individuals [10, 14]. ADHD per-
sisting beyond childhood has been shown to be
associated with increased negative sequelae including
antisocial behavior, and lower academic and occu-
pational achievement levels [14]. Thus, the develop-
mental course of ADHD has important clinical
implications. However little is known about the etio-
logical factors contributing to change in ADHD
severity over time [34].
There is a substantial genetic contribution to
ADHD, with twin studies reporting heritability esti-
mates of between 60 and 80% [35]. Molecular genetic
studies aimed at identifying risk gene variants for the
disorder have yielded a number of replicated findings.
The most widely replicated association is for a 48 bp
variable number tandem repeat (VNTR) variant
within the Dopamine D4 Receptor Gene (DRD4) [12,
13, 24, 26]. The second most robustly replicated
finding in pooled analyses is to a simple repeat se-
quence polymorphism (a CA(n) microsatellite mar-
ker) flanking the Dopamine Receptor D5 Gene
(DRD5) [24–26]. There are also replicated association
study findings for a 480 bp VNTR in the 3¢ UTR
(untranslated region) of the Dopamine transporter
Gene (DAT1, also known as Slc6a3). However, the
findings with DAT1 are less consistent, with one meta-
analysis yielding a small but significant association
[13] and four other meta-analyses reporting no
association [6, 24, 26, 30].
It has long been recognized that ADHD is a
clinically varied disorder, differing in the predomi-
nance of symptom dimensions, comorbid disorders,
and the clinical course over time [3]. Longitudinal
twin studies have shown a strong genetic contribu-
tion to ADHD symptom persistence [20, 22, 28, 29,
31]. As a result of these findings, it has been sug-
gested that genes influencing ADHD susceptibility
may also play a role in its temporal course [34].
ADHD which persists into adolescence and adult-
hood has been demonstrated to be more familial
than ADHD restricted to childhood [20]. It has also
been suggested that samples with a persistent form
of ADHD might reduce phenotypic and possibly
genetic heterogeneity, thereby increasing statistical
power to detect susceptibility gene variants associ-
ated with the disorder [11].
We set out to test these hypotheses by using the
most robustly associated ADHD susceptibility gene
variant detected so far, namely the DRD4 7 repeat
allele. Specifically, we postulated that this allele would
predict a worse developmental course in terms of
ADHD symptom severity, defined as the total number
of ADHD symptoms present. We also conducted
exploratory analyses of these associations for the
somewhat less well-established genetic risk factors
DRD5 and DAT1. Finally, allele frequencies for those
with baseline and ‘‘persistent’’ ADHD were compared
to those of controls.
Method
British Caucasian children aged between six and
twelve years, with suspected or diagnosed ADHD,
were originally recruited as part of a genetic study.
Child and Adolescent Psychiatrists and Paediatricians
in the Greater Manchester, South Wales and Avon
areas of the UK referred children to the study. The
children underwent an extensive assessment, includ-
ing research diagnostic interviews. Individuals were
excluded if they had a full scale IQ below 70, Tou-
rette’s syndrome, Pervasive Developmental Disorder
or any Neurological disorder including Epilepsy. The
ethnicity of participants (as well as their parents and
grandparents) was defined by the families themselves.
As this is a genetic study, ethnicity was assessed to
minimise genetic differences as the result of ethnic
differences between participants.
The sample for this longitudinal study was drawn
from an original cross-sectional study that included
375 children who met DSM-III-R/ DSM-IV criteria for
ADHD or ICD-10 criteria for Hyperkinetic Disorder at
baseline (mean age 9.2 years, SD = 2.1 years). If the
child was taking stimulant medication, parents were
interviewed regarding behaviour before medication
was administered. To improve the accuracy of retro-
spective phenotypic measurement, participants who
had been taking stimulant medication for more than a
year were excluded. More detail on the original cross-
sectional study and its findings can be found in
Holmes et al. [18], Langley et al. [21] and Whittinger
et al. [37]. The baseline genetic data have since been
expanded due to additional genotyping.
This current paper focuses on a new longitudinal
study of ADHD that included children from the ori-
ginal study who had reached adolescence. Five years
later, those individuals aged 12 years or over were
invited to participate in a follow up study. Of 198
individuals eligible, 190 were traced and 151 com-
pleted all components of reassessment (76% of those
eligible). The mean age at follow up was 14.5 years,
(SD = 1.7 years). Written informed consent from
parents and assent from children was received at each
wave of data collection. This study was reviewed and
gained approval from the North West Multicentre
Research Ethics Committee (UK).
j Measures
At baseline, parents (typically the mother) were
interviewed using the child and adolescent psychiatric
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assessment (CAPA) [2]. The CAPA is a semi struc-
tured interview which enables the presence or absence
of DSM-IV, DSM-III-R and ICD-10 symptoms and
diagnosis of childhood psychiatric disorders to be
determined. We used this measure to assess symp-
toms and diagnoses of ADHD, Conduct Disorder,
Oppositional Defiant Disorder and Mood disorders.
For ADHD, parents provided information regarding
the presence of each symptom. Individuals had to
demonstrate sufficient parent rated symptoms of the
disorder to obtain a diagnosis.
The presence of ADHD symptoms or impairment
in school, necessary for ICD-10 and DSM-IV diag-
noses of the disorder was assessed using the child
ADHD teacher telephone interview (ChATTI) [17].
Teacher ratings were used only to provide evidence of
pervasiveness of symptoms across situations.
At follow up, parents and adolescents were inter-
viewed using the CAPA-parent and child versions [1,
2] regardless of medication status. The teacher
ChATTI was again completed to ascertain symptoms
in a school setting. From this information, we gen-
erated a diagnostic subgroup of adolescents with
‘‘persistent’’ ADHD who continued to meet full DSM-
IV diagnostic criteria for ADHD at follow up (n = 93,
62%).
All interviewers were trained in house to a high
standard through intensive training by a child psy-
chiatrist with extensive experience of the CAPA (AT)
and by weekly supervision meetings by the same
individual. High rates of inter-rater reliability between
Time 1 and Time 2 were achieved with j coefficients
of 1.00 for diagnoses of ADHD.
j Genotyping information
DNA was extracted by phenol chlorophorm extrac-
tion from venous blood or buccal mouthwash sam-
ples. Genotyping of each of these markers has been
described in previous publications and was blind to
phenotypic status with respect to the measures pre-
sented in this paper. Briefly, genotyping of the DAT1
480 bp VNTR was performed using primers and
conditions described by Daly and colleagues [7] as
detailed in Holmes and colleagues [19] The DRD5
CA(n) microsatellite marker was genotyped on an
ABI 3100 capillary sequencer according to the
primers and conditions described by Sherrington
and colleagues [33]. For the DRD4 48 bp VNTR,
primer sets and analyses described previously were
used [8, 16, 36]. For some samples, adjacent SNPs
known to be in strong linkage disequilibrium with
the DRD4 7R VNTR [8, 36] were analyzed to confirm
the genotype.
j Control sample
Control data, previously utilised in studies of these
gene variants were available from the UK Blood
Transfusion Service and General Practice Registers.
All individuals were of British Caucasian origin. No
additional demographic or clinical information, was
available. For DRD4 [19] data from 442 controls were
available, for DRD5 data from 97 controls [38] and for
DAT1, there were data for 295 controls [19].
j Data analysis
For analysis of change in ADHD severity over time,
linear regression analysis was performed with risk
genotype as the independent variable and total
number of DSM-IV ADHD symptoms at reassessment
as the dependent variable, controlling for total num-
ber of DSM-IV ADHD symptoms at baseline. Where
univariate analyses were found to be significant,
analyses were repeated controlling for the significant
covariates of age, sex, current DSM-IV conduct dis-
order symptoms and medication. All independent
variables, including ADHD symptoms at baseline and
follow up, as well as all linear covariates were nor-
mally distributed. Allele frequencies for those with
baseline ADHD (all individuals) and ‘‘persistent’’
cases were compared to those for controls using
analysis of 2 · 2 contingency tables. Individuals were
classified as being ‘‘at risk’’ for a certain risk variant if
they possessed; one or more DRD4 48 bp VNTR 7-
repeat allele; one or more DRD5 (CA)n microsatellite
148 bp marker; and two copies of the DAT1 480 bp
VNTR 10-repeat allele.
Results
At follow up, 93 participants (62%) continued to meet
full diagnostic criteria for DSM-IV ADHD. 69%
(n = 64) of individuals with a diagnosis at Time 2
retained the same subtype diagnosis from Time 1 with
the majority of those who changed subtype moving
from Combined to either Inattentive or Hyperactive-
Impulsive subtype. There were no significant differ-
ences for baseline measures of gender, number of
ADHD, ODD or conduct disorder symptoms, between
those individuals who participated in the follow up
study (n = 151) and those who were eligible but did
not participate (n = 47), although there was a trend
for participants to be slightly younger (t = 1.88,
P = 0.06). The distributions of all variants for both
ADHD participants and control groups were in Hardy
Weinberg equilibrium.
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The mean number of DSM-IV ADHD symptoms at
baseline was 14.7 (SD = 2.4) and 12.2 (SD = 4.8) at
follow up. The mean ADHD symptom decline was
)2.5 (SD = 4.6). This difference was statistically sig-
nificant (b = 0.35, t = 4.53, P £ 0.001). All data were
normally distributed. At baseline, 23 individuals
(15%) met diagnostic criteria for DSM-IV conduct
disorder. At follow up 46 individuals (31%) met such
criteria.
j Change in ADHD severity over time
The DRD4 48 bp VNTR predicted the total number of
DSM-IV ADHD symptoms at follow up controlling for
total symptoms at baseline, even when the covariates
of age, gender and current conduct disorder symp-
toms were taken into account (r2 change = 0.04,
b = 0.20, t = 2.53, P = 0.01). The mean reduction in
ADHD symptoms also illustrated poorer prognosis
for those with the DRD4 7 repeat variant; those car-
rying the 7 repeat allele showing a mean reduction of
1.4 symptoms (SD = 3.7), those without the 7 repeat
allele showing a mean reduction of 3.3 symptoms
(SD = 4.5). The magnitude of the association was not
significantly different between baseline and follow up.
The DRD5 and DAT1 gene variants did not predict
ADHD symptom decline (see Table 1). Analysis of the
inattentive and hyperactive-impulsive symptom
dimensions separately indicated that this effect was
not specific to either dimension.
j Genetic variants predicting ADHD persistence
into adolescence
Case-control analysis revealed significant association
between the DRD4 48 bp VNTR 7-repeat allele and
‘‘persistent ADHD’’ (v2 = 15.41, df = 1, P £ 0.0001).
The odds ratio (OR) was 1.86 (95% CI: 1.30, 2.65,
P = 0.001) for diagnosis of the disorder at baseline
and 2.12 (95% CI: 1.45, 3.11, P < 0.0001) at follow up.
Similarly, the 148 bp risk allele of the DRD5 CA(n)
microsatellite marker also significantly predicted
baseline (v2 = 5.02, df = 1, P = 0.02, OR = 1.62, 95%
CI: 1.06, 2.47) persistent ADHD diagnosis (v2 = 5.78,
df = 1, P = 0.02, OR = 1.75, 95% CI: 1.11, 2.77). The
DAT1 variant was not associated with persistent
ADHD (v2 = 0.38, df = 1, P = 0.54) or baseline
ADHD (v2 = 0.26, df = 1, P = 0.61).
Discussion
The DRD4 48 bp VNTR significantly influenced de-
cline in ADHD symptoms over time, with those car-
rying the 7 repeat allele showing less than half the
decline in symptoms of those without the allele. Our
case-control analyses revealed significant associations
between ‘‘persistent’’ ADHD and the risk alleles in
DRD4 (VNTR 7 repeat) and DRD5 (148 bp allele) but
not with DAT1. For both associated variants, the odds
ratios were greater in the persistent ADHD sample
than in those with the baseline diagnosis but the
differences in magnitude of odds ratios were not
significant.
These findings suggest a role for the DRD4 VNTR
in the developmental course of ADHD as well as
increasing susceptibility for childhood ADHD. The
findings also support the hypothesis that some genes
that influence ADHD will also affect its developmental
course. To date, the focus of most psychiatric genetic
studies has been to identify genes that increase sus-
ceptibility to specific disorders, including ADHD.
Although this is an important goal, there is consid-
erable variation in the course of psychiatric disorders
such as ADHD over time. Identifying risk factors that
influence the developmental course of ADHD is an
additional and important aim. The risk factors and
causal pathways that influence developmental course
may be the same as those that increase susceptibility
to onset but they could also differ [34]. Our findings
support this hypothesis because the DRD4 and DRD5
Table 1 Linear regression analysis of gene variants predicting change in ADHD severity over time
R2 Unstandardised coefficients Standardised coefficients
b Standard error b t P-value
DRD4 48 bp VNTR
Baseline ADHD severity 0.001 0.26 0.42 0.05 0.62 0.54
Change in ADHD severity at follow up 0.04 1.72 0.68 0.20 2.53 0.01
DRD5 CA(n) microsatellite
Baseline ADHD severity <0.0001 0.31 0.25 0.14 1.23 0.22
Change in ADHD severity at follow up <0.0001 )0.13 0.79 )0.02 )0.17 0.87
DAT1 480 bp VNTR
Baseline ADHD severity 0.009 -0.43 0.40 )0.09 )1.09 0.28
Change in ADHD severity at follow up 0.002 0.48 0.74 0.05 0.65 0.52
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variants were both associated with the disorder, but
only the DRD4 7-repeat allele predicted the develop-
mental course.
Our case-control findings are in line with previ-
ous studies showing association between ADHD and
the DRD4 48 bp VNTR and the DRD5 CA(n)
microsatellite marker. The magnitude of the Odds
ratios for both variants was greater for the analysis
of persistent ADHD, however, unfortunately, the
number of non persistent individuals at follow up
(n = 58) was insufficient to directly compare the
differences between the persistent and non persistent
groups.
Identifying genetic and other risk factors that
influence the developmental course of ADHD is
important for several reasons. First, it is important to
identify the mechanisms that lead to poorer clinical
outcomes. Second, clinical resources such as intensity
of follow-up ideally need to be tailored according to
need. Predictors, both clinical and etiological, could
thus help target resources more effectively. The
identification of non-genetic factors and how they
may interact with genetic variants in influencing the
developmental course of ADHD is also an important
area for future research, although large longitudinal
samples will be needed when testing for Gene x
Environment interactions.
To date, to the best of our knowledge there have
been four other longitudinal molecular genetic
studies of ADHD. Our findings regarding DRD4 are
consistent with results from two of these. In the first
community-based study [9] the authors also found
that the influence of the DRD4 48 bp VNTR on
diagnosis of ADHD in boys increased with age. This
study, however, followed individuals only until the
age of 11 years and so did not assess the impact of
this variant during adolescence. It also had very
small numbers of participants with an ADHD diag-
nosis. The second study showed association between
the DRD4 7-repeat allele and worse adult psycho-
social outcome [27]. The third study followed 122
ADHD participants and 67 controls across three time
points during childhood, adolescence and young
adulthood, did not however demonstrate an associ-
ation between the DRD4 7 repeat allele and ADHD at
any time point (although various associations with
the DAT1 480 bp VNTR were reported) [4]. Finally,
a case-control study of 67 individuals with ADHD
found that possession of the 7-repeat allele was
associated with better clinical outcome (retaining a
diagnosis of combined type ADHD) [32]. However,
this last study differed from ours in having a sample
with a higher percentage of girls and higher IQ
scores.
These results suggest that although the DRD4
VNTR influences symptom decline, it is not possi-
ble to conclude that the DRD4 and DRD5 variants
are more strongly associated with ‘‘persistent
‘‘ADHD; the group who continue to meet full
diagnostic criteria at follow up. To date, there have
been few molecular genetic studies of adult ADHD,
but those that have been published suggest that the
DRD4 7 repeat allele is also a risk allele in this age
group. Thus far, there has been nothing to suggest
that the effect sizes of risk gene variants are greater
for adult or adolescent ADHD compared to child-
hood ADHD. However given our sample size we
could not test for differences because of a lack of
statistical power.
Although it would have been interesting to
compare presence of the risk alleles between those
with persistent and ‘‘non persistent’’ diagnoses at
follow up, the number of individuals without a
persistent diagnosis was too small. Moreover, al-
though not meeting DSM-IV diagnostic criteria for
ADHD at the adolescent follow up most individuals
(89% of the sample) still had ADHD symptoms and
impairment (which has important clinical implica-
tions) and therefore cannot truly be categorised as
‘‘non persistent’’. That is, there is no clear-cut,
clinically meaningful way of defining ‘‘non-persis-
tence’’.
As with any study, there are a number of limita-
tions of this design. First, the sample size for analysis
was modest. Nevertheless we still found evidence of
association at both time points for the most strongly
implicated susceptibility gene variant, the DRD4
VNTR. This modest sample size illustrates the need
for further replications of these findings in larger,
diverse samples.
Second, our findings that the DRD4 7 repeat allele
was associated with ADHD symptom severity at fol-
low-up but not baseline may be considered surpris-
ing. However, as all cases’ met diagnostic criteria for
ADHD at baseline, they also all had high ADHD
symptom counts in childhood (at baseline). There-
fore, the range for the number of symptoms was re-
stricted (8–18). By adolescence, the variation in
symptom scores was much greater (range 0–18).
Therefore, it is remains possible that that our sample
of clinical cases lacked power to detect childhood
ADHD severity as a result of limited variation in
symptom scores. Stimulant medication may have
influenced symptom severity at follow up. However,
controlling for medication in the analyses did not
alter the results.
In conclusion, the findings of our longitudinal
genetic study of ADHD indicate that the DRD4 7 re-
peat allele predicted a poorer developmental course
with carriers of the 7 repeat allele showing less than
half the ADHD symptom decline over a five year
period of those without the allele.
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